Prognostic factors in T3–Т4N0M0 breast cancer
https://doi.org/10.17650/1994-4098-2010-0-3-5-10
Abstract
The study used the records of clinical observations of 145 patients with locally advanced T3–Т4N0M0 breast cancer (BC) who were treated at the N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, in 1998 to 2003. Based on the examined combination of prognostic factors, the authors identified the criteria that had the greatest impact on the prognosis of primary T3–Т4N0M0 BC, which must the standard for its determination in this category of patients.
About the Authors
I. V. Vysotskaya
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. P. Letyagin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
K. V. Maksimov
Cancer Dispensary Four, South Administrative District, Moscow
Russian Federation
Russian Federation
References
1. Аксель Е.М., Давыдов М.И. Статистика злокачественных новообразований в России и странах СНГ. М., 2005.
2. Возный Э.К., Добровольская Н.Ю. 15-летний опыт комплексного лечения больных с местно-распространенным ра- ком молочной железы с использованием неоадъювантной химиотерапии. X Российский онкологический конгресс. Москва, 21–23 октября, 2006 г.; с. 14–6.
3. Летягин В.П., Хайленко В.А., Кочергина И.В. и др. Стандарты лечения больных первичным раком молочной железы. М.: РОНЦ РАМН, 2003.
4. Семиглазов В.Ф., Зернов К.Ю., Божок А.А. Воспалительная форма рака молочной железы (предсказывающие и прогностические факторы эффективности первичной химиотерапии). Вопр онкол 2006;(6).
5. Anikeeva N.V., Kravzov V.Y., Ellinidi V.N. Immunohistochemical investigation of expression of oncoprotein Her-2 in breast cancer with various estrogen-progesterone statuses. Proceedings of Endocrine Treatment and Prevention of Breast and Gynaecological Cancers 2006.
6. Ellinidi V.N., Anikeeva N.V., Goncharova О.A., Krasnozhon D.A. The NK cell (CD56, CD16) and Ki-67 antigen
7. in ЕR/PR negative human breast cancer. In: Abstracts of 4th International Congress on Autoimmunity, Budapest, 2004, November 3–7. Budapest, 2004; p. 90–1.
8. Guarneri V., Broglio K., Kau S.W. et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone recep tor status and other factors. J Clin Oncol 2006;24:1037–44.
9. Kilinc N., Yaldiz M. P53, с-b-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters. Eur J Gynecol Oncol 2004;25(2):606–10.
10. Pectasides D., Gagtia A., Arapantoni- Dadioti P. et al. Her-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006;26(I):647–53.
11. Petit T., Wilt M., Velten M. et al. Comparative value of tumor grade, hormonal receptors, Ki-67, Her-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant antracycline-bases chemotherapy. Eur J Cancer 2004;40(2):205–11.
Review
For citations:
Vysotskaya I.V., Letyagin V.P., Maksimov K.V. Prognostic factors in T3–Т4N0M0 breast cancer. Tumors of female reproductive system. 2010;(3):5-10. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-3-5-10
Views:
718
Email this article 